BioCentury
ARTICLE | Finance

Invest, not ingest

Why corporate VCs' parents rarely buy their portfolio companies

April 11, 2016 7:00 AM UTC

There are myriad reasons for pharma and big biotech to make investments in fledgling companies through corporate venture arms, but data suggest M&A is not one of them.

The latest example is Nimbus Therapeutics LLC, which last week sold its Nimbus Apollo Inc. subsidiary to Gilead Sciences Inc. (NASDAQ:GILD) for $400 million up front and up to $800 million in development milestones...